<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35466438</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2125</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>British journal of clinical pharmacology</Title>
          <ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bcp.15362</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Acalabrutinib, a selective Bruton tyrosine kinase inhibitor is approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Many critically ill patients are unable to swallow and need oral medications to be delivered via a nasogastric (NG) tube. Furthermore, critically ill patients are typically administered proton-pump inhibitors (PPIs) to prevent stress ulcers. Concomitant administration with PPIs reduces acalabrutinib exposure and is not currently recommended. To evaluate acalabrutinib in subjects co-administered with PPIs who require NG delivery, a Phase 1, open-label, randomized, crossover, single-dose study was conducted in healthy subjects.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The study assessed the relative bioavailability of an acalabrutinib suspension-in regular, degassed Coca-ColaÂ®-administered via NG tube (Acala-NG) versus the pharmacokinetics (PK) of an acalabrutinib capsule administered orally with water. In addition, the PPI effect was evaluated by comparing the PK following Acala-NG in the presence or absence of rabeprazole.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Exposure of acalabrutinib and its active metabolite (ACP-5862) were comparable following administration of Acala-NG versus the oral capsule (Geo mean ratio, % ref [90% CI]: acalabrutinib AUC<sub>inf</sub> : 103 [93-113]; C<sub>max</sub> : 144 [120-173]). In addition, exposure was similar following administration of Acala-NG with and without a PPI (Geo mean ratio, % ref [90% CI]: acalabrutinib AUC<sub>inf</sub> : 105 [79-138]; C<sub>max</sub> : 95 [66-137]). No safety or tolerability concerns were observed, and all adverse events were mild and resolved without treatment.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Acala-NG with or without a PPI, is safe and well-tolerated without impeding bioavailability.</AbstractText>
          <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sharma</LastName>
            <ForeName>Shringi</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-3120-225X</Identifier>
            <AffiliationInfo>
              <Affiliation>Quantitative Clinical Pharmacology, AstraZeneca, South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pepin</LastName>
            <ForeName>Xavier</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>New Modalities &amp; Parenteral Development, Pharmaceutical Technology &amp; Development, Operations, AstraZeneca, Macclesfield, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheung</LastName>
            <ForeName>Jean</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Hematology, Research and Development, AstraZeneca, South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Lianqing</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Late Hematology Statistics, Oncology Biometrics, AstraZeneca, South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Hua</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma (a member of the AstraZeneca Group), South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Townsley</LastName>
            <ForeName>Danielle</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Research and Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Parexel International Early Phase Clinical Unit (Los Angeles), Glendale, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Majewski</LastName>
            <ForeName>Michal</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Research and Development, Clinical Operations, AstraZeneca, Toronto, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ware</LastName>
            <ForeName>Joseph A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma (a member of the AstraZeneca Group), South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mann</LastName>
            <ForeName>James</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Oral Product Development, Pharmaceutical Technology &amp; Development, Operations, AstraZeneca, Macclesfield, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Munugalavadla</LastName>
            <ForeName>Veerendra</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Medicine, Hematology, Research and Early Development, AstraZeneca, South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sheridan</LastName>
            <ForeName>Louise</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Product Leadership, Pharmaceutical Technology &amp; Development, Operations, AstraZeneca, Macclesfield, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Priti</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Development Hematology, Oncology Research and Development, AstraZeneca, South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gupta</LastName>
            <ForeName>Ashok</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Research and Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tomkinson</LastName>
            <ForeName>Helen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology &amp; Quantitative Pharmacology (CPQP), Clinical Pharmacology and Safety Sciences, Research and Development, AstraZeneca, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Br J Clin Pharmacol</MedlineTA>
        <NlmUniqueID>7503323</NlmUniqueID>
        <ISSNLinking>0306-5251</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Acalabrutinib</Keyword>
        <Keyword MajorTopicYN="N">nasogastric delivery</Keyword>
        <Keyword MajorTopicYN="N">proton pump inhibitor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35466438</ArticleId>
        <ArticleId IdType="doi">10.1111/bcp.15362</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
